2. Search Result
Search Result
Results for "

1.03

" in MedChemExpress (MCE) Product Catalog:

173

Inhibitors & Agonists

2

Screening Libraries

1

Fluorescent Dye

4

Biochemical Assay Reagents

18

Peptides

7

Inhibitory Antibodies

5

Natural
Products

22

Recombinant Proteins

6

Antibodies

1

Click Chemistry

22

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-144876
    RIDR-PI-103

    		Reactive Oxygen Species Cancer
    RIDR-PI-103 is a reactive oxygen species (ROS)-induced drug release prodrug with a self-cyclizing moiety linked to a pan-PI3K inhibitor (PI-103).
    RIDR-PI-103
  • HY-10115
    PI-103
    Maximum Cited Publications
    22 Publications Verification

    		 PI3K mTOR DNA-PK Autophagy Apoptosis Cancer
    PI-103 is a potent PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 also inhibits DNA-PK with an IC50 of 2 nM. PI-103 induces autophagy .
    PI-103
  • HY-10115A
    PI-103 Hydrochloride
    Maximum Cited Publications
    22 Publications Verification

    		 PI3K mTOR DNA-PK Autophagy Apoptosis Cancer
    PI-103 Hydrochloride is a dual PI3K and mTOR inhibitor with IC50s of 8 nM, 88 nM, 48 nM, 150 nM, 20 nM, and 83 nM for p110α, p110β, p110δ, p110γ, mTORC1, and mTORC2. PI-103 Hydrochloride also inhibits DNA-PK with an IC50 of 2 nM. PI-103 Hydrochloride induces autophagy .
    PI-103 Hydrochloride
  • HY-18259
    103D5R

    		HIF/HIF Prolyl-Hydroxylase Cancer
    103D5R (Compound 15) is an inhibitor for the activation of hypoxia-inducible factor-1 (HIF-1) with an IC50 of 35 µM, through reduction of the HIF-1α protein synthesis. 103D5R inhibits the proliferation of LN229 with IC50 of 26 µM .
    103D5R
  • HY-D1471
    10-(3-Sulfopropyl)acridinium Betaine

    		Fluorescent Dye Others
    10-(3-Sulfopropyl)acridinium Betaine is a fluorescent dye with high durability (>3 months) .
    10-(3-Sulfopropyl)acridinium Betaine
  • HY-NP103
    Highly purified Type III collagen, from bovine skin

    Bovine Type III collagen, immunization grade

    		 MMP Inflammation/Immunology
    Highly purified Type III collagen, from bovine skin (Bovine Type III collagen, immunization grade) is an immune grade collagen derived from bovine skin, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .
    Highly purified Type III collagen, from bovine skin
  • HY-12487
    NL-103

    		HDAC Hedgehog Gli Cancer
    NL-103 is an inhibitor of histone deacetylases (HDACs) and Hedgehog, with the IC50 values ​​of 21.3 nM, 57 nM, 74 nM, and 680 nM for HDAC1, HDAC2, HDAC3, and HDAC6, respectively. NL-103 can downregulate the expression of Gli2. NL-103 can be used in anti-cancer research .
    NL-103
  • HY-158980
    Antifungal agent 103

    		Fungal Bacterial Infection
    Antifungal agent 103 (compound 7y) is a potent antifungal agent. Antifungal agent 103 inhibits R. solani with an EC50 of 0.47 μg/mL .
    Antifungal agent 103
  • HY-146470
    Antibacterial agent 103

    		Bacterial Infection
    Antibacterial agent 103 (compound 7) has highly antibacterial activity against kinds of Gram-positive and -negative bacteria. Antibacterial agent 103 can be used for researching inhibition of resistance bacterial strains .
    Antibacterial agent 103
  • HY-155503
    Antitumor agent-103

    		Apoptosis Cancer
    Antitumor agent-103 (compound 24l) is an apoptosis inducer with antiproliferative and anti-clony formation activities. Antitumor agent-103 arrests cell cycle at G0/G1 phase, enhances NO production, and exhibits anti-tumor activity .
    Antitumor agent-103
  • HY-163354
    EGFR-IN-103

    		EGFR Cancer
    EGFR-IN-103 (compound 1) is a potent EGFR inhibitor with an IC50 of 6 nM for pEGFR .
    EGFR-IN-103
  • HY-111315
    XEN103

    		Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    XEN103 is a SCD1 inhibitor, with IC50s of 14 nM and 12 nM for mSCD1 and SCD1 in HepG2 cell. XEN103 can be used for research of obesity and type 2 diabetes. XEN103 also induces sebaceous gland atrophy in mice .
    XEN103
  • HY-134955
    VT103
    2 Publications Verification

    		 YAP Cancer
    VT103, an analog of VT101, is an orally active and selective TEAD1 protein palmitoylation inhibitor. VT103 inhibits YAP/TAZ-TEAD promoted gene transcription, blocks TEAD auto-palmitoylation, and disrupts interaction between YAP/TAZ and TEAD. VT103 can be used for the research of cancer .
    VT103
  • HY-149216
    Anticancer agent 103

    		Others Cancer
    Anticancer agent 103 (Compound 2k) is a potent anticancer agent .
    Anticancer agent 103
  • HY-101203A
    GJ103 sodium
    1 Publications Verification

    		 Others Metabolic Disease Cancer
    GJ103 sodium is a read-through compound that can induce read through of premature stop codons. GJ103 sodium has potential for the research of genetic disorders caused by nonsense mutations .
    GJ103 sodium
  • HY-101203
    GJ103

    		Others Metabolic Disease Cancer
    GJ103 is a read-through compound that can induce read through of premature stop codons. GJ103 has potential for the research of genetic disorders caused by nonsense mutations .
    GJ103
  • HY-P6053
    KK-103

    		Opioid Receptor Neurological Disease
    KK-103 is a precursor of leucine-enkephalin (Leu-ENK) overcomes high proteolytic instability of Leu-ENK via markedly increased plasma stability in mice that has antinociceptive effect .
    KK-103
  • HY-13758A
    TAS-103 dihydrochloride
    1 Publications Verification

    BMS-247615 dihydrochloride

    		 Topoisomerase Cancer
    TAS-103 dihydrochloride is a dual inhibitor of DNA topoisomerase I/II, used for cancer research.
    TAS-103 dihydrochloride
  • HY-13758
    TAS-103

    BMS-247615

    		 Topoisomerase Cancer
    TAS-103 is a dual inhibitor of DNA topoisomerase I/II, used for cancer research.
    TAS-103
  • HY-117992
    BR103

    		Complement System Others
    BR103 is a C3aR-specific small molecule ligand. BR103 can be used to measure ligand affinity for a G protein-coupled receptor for saturation and competitive binding .
    BR103
  • HY-14162
    AM103 free acid

    		FLAP Inflammation/Immunology
    AM103 (free acid) is a selective FLAP inhibitor that can block the first step of the LT pathway, which is 5-LO activation. AM103 (free acid) can inhibit the production of LTB4 and cysteinyl leukotrienes (CysLT). AM103 (free acid) has anti-inflammatory activity in a mouse model of chronic lung inflammation and can extend the survival time of mice injected with platelet-activating factor. AM103 (free acid) can be used for research on respiratory diseases such as asthma .
    AM103 free acid
  • HY-129118
    Takeda103A

    		Others Cardiovascular Disease
    Takeda103A is a potent inhibitor of GRK2. G protein-coupled receptors (GPCRs) are central to many physiological processes. Takeda103A has the potential for the research of heart failure .
    Takeda103A
  • HY-W440743
    BP Lipid 103

    		Liposome Cancer
    BP Lipid 103 is an amine ionizable lipid analogous to SM-102. It can be used to prepare liposome or lipid nanoparticles.
    BP Lipid 103
  • HY-152098
    HX103

    		EGFR Cancer
    HX103 is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-based fluorogenic probe. HX103 inhibits EGFR 19 del, EGFR L858R, EGFR wild type and EGFR T790M with IC50s of 1.3, 1.5, 4.0 and 977 nM, respectively. HX103 can be used for quantifying active-EGFR to predict agent sensitivity in NSCLC patients with EGFR-activating mutations .
    HX103
  • HY-14163
    AM103

    		FLAP Inflammation/Immunology
    AM 103 is a potent and selective FLAP inhibitor, with an IC50 value of 4.2 nM.
    AM103
  • HY-135145
    Limantrafin
    5+ Cited Publications

    CB-103

    		 Notch Cancer
    Limantrafin (CB-103) is a first-in-class, orally active protein-protein interaction (PPI) inhibitor of the NOTCH transcriptional activation complex. Limantrafin has anti-tumor activity .
    Limantrafin
  • HY-161979
    HSD17B13-IN-103

    		17β-HSD Cancer
    HSD17B13-IN-103 (Compound 44) is a HSD17B13 inhibitor. HSD17B13-IN-103 can be used in the study of non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) .
    HSD17B13-IN-103
  • HY-14557A
    Pimavanserin hemitartrate
    10+ Cited Publications

    ACP-103 hemitartrate

    		 5-HT Receptor Neurological Disease
    Pimavanserin (ACP-103) hemitartrate is a potent 5-HT 2A receptor inverse agonist with pIC50 and pKi of 8.73 and 9.3, respectively.
    Pimavanserin hemitartrate
  • HY-P99796
    Ozoralizumab

    ATN-103

    		 TNF Receptor Inflammation/Immunology
    Ozoralizumab (ATN-103) is an anti-TNFα humanized antibody. Ozoralizumab is a humanized trivalent nanobody compound that consists of two anti-human TNFα nanobodies and an anti-human serum albumin (HSA) nanobody. Ozoralizumab can be used in research of arthritis .
    Ozoralizumab
  • HY-117087
    K103

    		Phosphatase Cancer
    K103 is an inhibitor discovered from the screen that is an analog of the serotonin antagonist benzazocine. K103 exhibited inhibition of SHIP homologues, labelling it a pan-SHIP1/2 inhibitor, but the molecule had no effect on another 5' inositol phosphatase, OCRL. In line with the "two PIPs hypothesis", the molecule exhibited significant anti-tumour effects against a variety of cell lines, particularly breast cancer cells. Additional studies with K103 revealed that inhibition of SHIP1/2 in multiple myeloma cells resulted in G2/M cell cycle arrest followed by extensive apoptosis via activation of the caspase cascade. K103 fits the commonly used small molecule agent property profile, but while this work was being conducted, it was discovered that K103 caused psychoactive effects in mice, which limited the utility of the molecule in vivo. Therefore, certain synthetic studies were conducted on this tryptamine to identify the features that needed to be present in the molecule to maintain pan-SHIP1/2 inhibition in order to design an inhibitor with favourable pharmacodynamic properties and an improved side effect profile.
    K103
  • HY-P2499
    BAD (103-127) (human), FAM-labeled

    		Bcl-2 Family Cancer
    BAD (103-127) (human), FAM-labeled is a FAM-labeled human BAD (103-127) (HY-P2468). BAD (103-127) (human), the 25-mer Bad peptide, is derived from the BH3 domain of BAD, can antagonize the function of Bcl-xL .
    BAD (103-127) (human), FAM-labeled
  • HY-15660
    Efinaconazole
    2 Publications Verification

    KP-103

    		 Fungal Infection
    Efinaconazole (KP-103) is a triazole antifungal agent and againsts T. mentagrophytes SM-110 and C. albicans ATCC 10231 with MICs of 0.0039 μg/mL and 0.00098 μg/mL, respectively . Efinaconazole has a potent in vitro activity against fungal pathogens including dermatophytes, Candida and Malassezia species .
    Efinaconazole
  • HY-17548
    VMY-1-103

    		Caspase Apoptosis Cancer
    VMY-1-103 is an inhibitor for cyclin/Cdk complex, that arrests the cell cycle at G1 phase. VMY-1-103 reduces mitochondrial membrane potential, induces p53 phosphorylation and and PARP cleavage, activates caspase-3, and thus induces apoptosis in prostate cancer cell LNCaP .
    VMY-1-103
  • HY-P2468
    BAD (103-127) (human)

    BADBH3 103-127 (human); BADBH3 (human)

    		 Bcl-2 Family Cancer
    BAD (103-127) (human), the 25-mer Bad peptide, is derived from the BH3 domain of BAD, can antagonize the function of Bcl-xL. BAD (103-127) (human) is reported to have almost 800-fold higher affinity for Bcl-XL than the 16-mer peptide .
    BAD (103-127) (human)
  • HY-157754
    E3 Ligase Ligand-linker Conjugate 103

    		E3 Ligase Ligand-Linker Conjugates Cancer
    E3 Ligase Ligand-linker Conjugate 103 is a conjugate of E3 ligase ligand and linker, consisting of (S,R,S)-AHPC (HY-125845) and the corresponding Linker. (S,R,S)-AHPC is a VH032-based von Hippel-Lindau (VHL) ligand that recruits VHL proteins. E3 Ligase Ligand-linker Conjugate 103 can be used as a key intermediate for the synthesis of complete PROTAC molecules.
    E3 Ligase Ligand-linker Conjugate 103
  • HY-P10301
    CXCL9(74-103)

    		CXCR Cancer
    CXCL9(74-103) is a derivative peptide of CXCL9 that has a high affinity for glycosaminoglycans (GAGs) and can bind to GAGs. CXCL9(74-103) possesses anti-angiogenic properties, capable of reducing EGF, VEGF165, and FGF-2-mediated angiogenesis processes in vitro, without exhibiting cytotoxicity .
    CXCL9(74-103)
  • HY-R00040
    hsa-miR-103a-3p mimic

    		MicroRNA Cancer
    hsa-miR-103a-3p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-103a-3p mimic
    hsa-miR-103a-3p mimic
  • HY-P1698
    Reltecimod

    AB-103

    		 Bacterial CD28 Infection Inflammation/Immunology Cancer
    Reltecimod (AB-103) is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod can be used to research necrotizing soft-tissue infections (NSTIs) .
    Reltecimod
  • HY-RS02024
    CCDC103 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CCDC103 Human Pre-designed siRNA Set A contains three designed siRNAs for CCDC103 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CCDC103 Human Pre-designed siRNA Set A
    CCDC103 Human Pre-designed siRNA Set A
  • HY-162426
    UNC-CA2-103

    		Others Cancer
    UNC-CA2-103 (compound 128) is a potent inhibitor of Tousled like kinase 2 (TLK2), with the IC50 of 18 nM .
    UNC-CA2-103
  • HY-R00038
    hsa-miR-103a-1-5p mimic

    		MicroRNA Cancer
    hsa-miR-103a-1-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-103a-1-5p mimic
    hsa-miR-103a-1-5p mimic
  • HY-R00039
    hsa-miR-103a-2-5p mimic

    		MicroRNA Cancer
    hsa-miR-103a-2-5p mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-103a-2-5p mimic
    hsa-miR-103a-2-5p mimic
  • HY-RS03679
    DEFB103A Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    DEFB103A Human Pre-designed siRNA Set A contains three designed siRNAs for DEFB103A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    DEFB103A Human Pre-designed siRNA Set A
    DEFB103A Human Pre-designed siRNA Set A
  • HY-P2291
    Beta-defensin 103 isoform X1, pig

    		Bacterial Inflammation/Immunology
    Beta-defensin 103 isoform X1, pig is an antimicrobial peptide found in different living organisms, involved in the first line of defense in their innate immune response against pathogens .
    Beta-defensin 103 isoform X1, pig
  • HY-RI00040
    hsa-miR-103a-3p inhibitor

    		MicroRNA Cancer
    hsa-miR-103a-3p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-103a-3p inhibitor
    hsa-miR-103a-3p inhibitor
  • HY-P10132
    PRDX3(103-112), human

    		Ferroptosis Metabolic Disease
    PRDX3(103-112), human is a marker for ferroptosis. PRDX3 is hyperoxidated by mitochondrial lipid peroxides. PRDX3 inhibits cystine uptake after hyperoxidization .
    PRDX3(103-112), human
  • HY-P2291A
    Beta-defensin 103 isoform X1, pig TFA

    		Bacterial Inflammation/Immunology
    Beta-defensin 103 isoform X1, pig TFA is an antimicrobial peptide found in different living organisms, involved in the first line of defense in their innate immune response against pathogens .
    Beta-defensin 103 isoform X1, pig TFA
  • HY-P1698B
    Reltecimod TFA

    AB-103 TFA

    		 Bacterial CD28 Infection Inflammation/Immunology Cancer
    Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs) .
    Reltecimod TFA
  • HY-P1735
    Moth Cytochrome C (MCC) (88-103)

    		Cytochrome P450 Inflammation/Immunology
    Moth Cytochrome C (MCC) (88-103), derived from the carboxyl terminus of moth cytochrome c, induces positive selection of TCR transgenic thymocytes .
    Moth Cytochrome C (MCC) (88-103)
  • HY-RI00038
    hsa-miR-103a-1-5p inhibitor

    		MicroRNA Cancer
    hsa-miR-103a-1-5p inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-103a-1-5p inhibitor
    hsa-miR-103a-1-5p inhibitor

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: